Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis
Go back to Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bis| (NASDAQ: CBIO) | Delayed: 13.17 +0.10 (0.77%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.07 | 52 Week High | $4.57 | |||
| Open | $13.16 | 52 Week Low | $0.62 | |||
| Day High | $13.81 | P/E | N/A | |||
| Day Low | $13.12 | EPS | $0.00 | |||
| Volume | 250,371 | |||||



